Equities
  • Price (EUR)29.12
  • Today's Change-0.22 / -0.75%
  • Shares traded0.00
  • 1 Year change-40.57%
  • Beta--
Data delayed at least 15 minutes, as of Apr 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CompuGroup Medical SE & Co. KGaA is a Germany-based company engaged in the enterprise software development. The Company focuses on providing software solutions to healthcare institutions. The activities are divided into six segments: Ambulatory Software Services (AIS), providing practice management software and medical records; Pharmacy Information Systems (PCS), including integrated clinical, administrative and financial software applications for pharmacies; Hospital Information Systems (HIS), such as laboratory and special care information systems; Communication & Data (C&D), offering software interfaces for pharmaceutical and medical equipment manufacturers; provides Picture Archiving and Communication Systems (PACS); Workflow & Decision Support (WDS), delivering software for management support aimed at healthcare payers, such as health insurers and managed care companies, and Internet Service Provider (ISP), providing Internet for healthcare providers.

  • Revenue in EUR (TTM)1.19bn
  • Net income in EUR45.92m
  • Incorporated2020
  • Employees9.20k
  • Location
    CompuGroup Medical SE & Co KgaAMaria Trost 21KOBLENZ 56070GermanyDEU
  • Phone+49 26180000
  • Fax+49 26 180001166
  • Websitehttps://www.cgm.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
COPX.N:GER since
announced
Transaction
value
m.Doc GmbHDeal completed24 Apr 202324 Apr 2023Deal completed-41.42%--
Data delayed at least 15 minutes, as of Apr 19 2024 15:46 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.